Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28567279 | 0.87 | PDE10A (0.50) | ALDH1A1MEN1KMT2ARAB9APDE10A | |
| SCHEMBL29940575 | 0.86 | PDE10A (0.60) | ALDH1A1TDP1MEN1KMT2ARAB9A | |
| SCHEMBL6512953 | 0.86 | PDE10A (0.60) | ALDH1A1TDP1MEN1KMT2ARAB9A | |
| SCHEMBL14089956 | 0.85 | TRPV1 (0.58) | ALDH1A1TDP1PDE10ATRPV1POLB | |
| SCHEMBL7841891 | 0.85 | PDE10A (0.55) | ALDH1A1TDP1MEN1KMT2ARAB9A | |
| SCHEMBL1736168 | 0.84 | MEN1 (0.57) | ALDH1A1TDP1MEN1KMT2ARAB9A | |
| SCHEMBL1736457 | 0.84 | PAX8 (0.57) | ALDH1A1TDP1MEN1KMT2ARAB9A | |
| SCHEMBL1738384 | 0.84 | MAPT (0.52) | ALDH1A1TDP1MEN1KMT2ARAB9A | |
| SCHEMBL30269976 | 0.84 | CYP2A6 (0.54) | ALDH1A1PDE10ATRPV1POLBNPC1 | |
| SCHEMBL27930436 | 0.84 | TRPV1 (0.51) | ALDH1A1TDP1MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6558650-B1 | Exposing tumor cells to a nifedipine photodegradation product; | OREGON HEALTH AND SCIENCE UNIVERSITY | 2003-05-06 | — | — | US | claimed |
| EP-1069918-A4 | ENHANCEMENT OF CELLULAR GALLIUM UPTAKE | UNIV OREGON HEALTH SCIENCES (US) | 2002-02-20 | — | — | EP | claimed |
| EP-1069918-A1 | ENHANCEMENT OF CELLULAR GALLIUM UPTAKE | Oregon Health Sciences University (US) | 2001-01-24 | — | — | EP | claimed |
| WO-1999051277-A1 | ENHANCEMENT OF CELLULAR GALLIUM UPTAKE | OREGON HEALTH SCIENCES UNIVERSITY (US) | 1999-10-14 | — | — | WO | claimed |
| US-12043730-B2 | Fused deposition modeling type additive manufacturing material | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-07-23 | — | — | US | disclosed |
| CN-118239988-A | Preparation method and application of heterochiral binuclear Ir (III) metal-organic double-helix structure compound | 大连理工大学 | 2024-06-25 | — | — | CN | disclosed |
| US-11723269-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-11723269-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-11723269-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| EP-3238711-B1 | BASE FOR SOLID DISPERSION, PRODUCTION METHOD FOR SOLID DISPERSION USING SAME, AND SOLID DISPERSION | MITSUBISHI CHEM CORP (JP) | 2023-07-12 | — | — | EP | disclosed |
| EP-3831879-B1 | MATERIAL FOR FUSED DEPOSITION MODELING TYPE ADDITIVE MANUFACTURING | MITSUBISHI CHEM CORP (JP) | 2023-07-12 | — | — | EP | disclosed |
| EP-4032527-A1 | STABLE NIMODIPINE PARENTERAL FORMULATION | Grace Therapeutics Inc. (US) | 2022-07-27 | — | — | EP | disclosed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | disclosed |
| EP-1119356-A1 | RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2001-08-01 | — | — | EP | disclosed |
| US-6241964-B1 | (F18)(2-FLUOROMETHOXY-5-(5-TRIFLUOROMETHYL-TETRAZOLE-1-YL) -BENZYL)-((2S,3S)-2-PHENYL-PIPERIDINE-3-YL)-AMINE OR SALT; HUMAN BRAIN TISSUE IMAGING USING POSITRON EMISSION TOMOGRAPHY | MERCK & CO., INC. | 2001-06-05 | — | — | US | disclosed |
| EP-0998304-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLODEXTRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-10 | — | — | EP | disclosed |
| WO-2000018403-A1 | RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-04-06 | — | — | WO | disclosed |
| WO-1998055148-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLODEXTRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-10 | — | — | WO | disclosed |
| US-4886822-A | SIDE EFFECT REDUCTION | KOWA COMPANY, LTD. (JP) | 1989-12-12 | — | — | US | disclosed |
| EP-0286979-A1 | Substituted anilide derivatives | KOWA COMPANY, LTD. (JP) | 1988-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723269-B2 | Organic electroluminescent materials and devices | PUF60, CD99, DDT | ALDH1A1 1307/4885TDP1 3123/4885MEN1 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.